Danyal Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Danyal Ibrahim has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Mark Wake
3 shared publicationsSachio Takeno
Department of Otolaryngology, Hospital for Sick Children, Toronto, Ontario, Canada
3 shared publicationsBlake Froberg
Indiana Poison Center, Methodist Hospital, Clarian Health Partners, Indiana University School of Medicine, Indianapolis, IN 46206-1367, USA
2 shared publicationsDorothy B. Wakefield
Research Department, Saint Francis Hospital and Medical Center, Hartford CT, United States
2 shared publicationsJennifer Puff
Diabetes and Endocrinology Center, Saint Francis Hospital and Medical Center, Hartford, CT, United States
2 shared publicationsKendra Williams
Research Department, Saint Francis Hospital and Medical Center, Hartford CT, United States
2 shared publications
Latest Publications
- 12 January 2021
- Published by Taylor & Francis in Hospital Practice
- Vol. 49 (2) , 127-132
Impact of a hospital unit-based leadership triad on key performance metrics
We piloted a triad leadership model consisting of a unit-based hospitalist medical director, nurse manager, and case manager on five medical inpatient units. The purpose of this explanatory case study was to determine what, if any, impact the triad team would have on commonly measured operational and quality metrics: observed to expected length of stay, likelihood to recommend the hospital, hand-washing compliance, all cause 30 day readmission rates, percent of discharges by noon, and percent of discharge to skilled nursing facilities. Over the course of a year triad units demonstrated improvement in most metrics in comparison to the baseline period. While trends for the metrics were favorable, most striking was a statistically significant improvement in the observed to expected length of stay ratio (1.25 to 1.15, p < 0.001) which is the organization’s most widely-used marker for efficient hospital patient flow.
- 12 January 2021
- Published by Taylor & Francis in Hospital Practice
- Vol. 49 (2) , 127-132
Impact of a hospital unit-based leadership triad on key performance metrics
We piloted a triad leadership model consisting of a unit-based hospitalist medical director, nurse manager, and case manager on five medical inpatient units. The purpose of this explanatory case study was to determine what, if any, impact the triad team would have on commonly measured operational and quality metrics: observed to expected length of stay, likelihood to recommend the hospital, hand-washing compliance, all cause 30 day readmission rates, percent of discharges by noon, and percent of discharge to skilled nursing facilities. Over the course of a year triad units demonstrated improvement in most metrics in comparison to the baseline period. While trends for the metrics were favorable, most striking was a statistically significant improvement in the observed to expected length of stay ratio (1.25 to 1.15, p < 0.001) which is the organization’s most widely-used marker for efficient hospital patient flow.
- 1 December 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (6) , 102922
SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma
- 1 December 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (6) , 102922
SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma
- Open Access
- 20 September 2020
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 9 (4) , 913-926
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was discovered in Wuhan City, Hubei Province, China, in December 2019. As of September 6, 2020, confirmed cases have risen to more than 27,000,000 worldwide and more than 885,000 people have died. Currently, no cure or standard treatment for COVID-19 exists. We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized patients with COVID-19. Methods Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge. Results Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in the disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p < 0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p < 0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed. Conclusions Our results suggest that convalescent plasma with adequate anti-SARS-CoV-2 antibody titer is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease. Trial Registration ClinicalTrials.gov. Identifier, NCT04343261, IND #19805.
- 20 September 2020
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 9 (4) , 913-926
Open AccessFactors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was discovered in Wuhan City, Hubei Province, China, in December 2019. As of September 6, 2020, confirmed cases have risen to more than 27,000,000 worldwide and more than 885,000 people have died. Currently, no cure or standard treatment for COVID-19 exists. We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized patients with COVID-19. Methods Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge. Results Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in the disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p < 0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p < 0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed. Conclusions Our results suggest that convalescent plasma with adequate anti-SARS-CoV-2 antibody titer is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease. Trial Registration ClinicalTrials.gov. Identifier, NCT04343261, IND #19805.
- Open Access
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized COVID-19 patients. Convalescent plasma with sufficient IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge. Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p<0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p<0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed. Our results suggest that convalescent plasma is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease.
Open AccessFactors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized COVID-19 patients. Convalescent plasma with sufficient IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge. Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p<0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p<0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed. Our results suggest that convalescent plasma is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease.
- 1 January 2020
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 48 (1) , 471
983: EVALUATION OF ICATIBANT IN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR-INDUCED ANGIOEDEMA
- 1 January 2020
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 48 (1) , 471
983: EVALUATION OF ICATIBANT IN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR-INDUCED ANGIOEDEMA
- 6 July 2019
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 39 (9) , 881-888
High‐Dose Gabapentin for the Treatment of Severe Alcohol Withdrawal Syndrome: A Retrospective Cohort Analysis
Study Objective: Gabapentin has been proved to be beneficial in promoting abstinence, decreasing alcohol cravings, and improving mood and sleep quality when given at higher doses; however, data are limited regarding the efficacy and safety of using high‐dose gabapentin as part of the treatment of alcohol withdrawal syndrome ( AWS ). The aim of this study was to evaluate the impact of high‐dose gabapentin on benzodiazepine requirements, alcohol withdrawal symptoms, and hospital length of stay in patients hospitalized with AWS . Design: Retrospective cohort study. Setting: Large academic medical center. Patients: All adults presenting to the emergency department between January 2015 and April 2018 with a diagnosis of severe AWS (Clinical Institute Withdrawal Assessment for Alcohol Scale, Revised [ CIWA ‐Ar] score ≥ 15) and prescribed the institution's alcohol withdrawal agitated delirium protocol were eligible for inclusion in the study. Of these, 50 patients who received high‐dose gabapentin (≥ 1800 mg/day) in the first 48 hours of hospital admission (treatment group) were propensity score–matched to 50 patients who did not receive gabapentin (control group). Measurements and Main Results: Patients who received high‐dose gabapentin required a significantly lower overall amount of benzodiazepines (mean ± SD 109.5 ± 53.4 mg vs 88.5 ± 35.6 mg [lorazepam equivalents], p=0.023) and had a significantly lower mean CIWA ‐Ar score (10.1 ± 4.7 vs 7.7 ± 3.9, p=0.010) and maximum CIWA ‐Ar score (16.0 ± 7.0 vs 12.6 ± 6.1, p=0.016) on day 3 of hospitalization. The high‐dose gabapentin regimen was well tolerated, without an increased risk of oversedation, compared with the control group (Richmond Agitation‐Sedation Scale score < −1: 34% in the treatment group vs 20% in the control group, p=0.115). Patients receiving high‐dose gabapentin had a shorter length of hospital stay (7.4 ± 4.0 days vs 6.0 ± 2.6 days, p=0.034) and increased likelihood of being discharged home (66% vs 88%, p=0.009) compared with the control group. Conclusion: Early initiation of high‐dose gabapentin was associated with a significant reduction in benzodiazepine exposure, faster stabilization of alcohol withdrawal–related symptoms, and shorter hospital length of stay. Future studies evaluating gabapentin's effect on long‐term safety and hospital readmission are warranted.
- 6 July 2019
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 39 (9) , 881-888
High‐Dose Gabapentin for the Treatment of Severe Alcohol Withdrawal Syndrome: A Retrospective Cohort Analysis
Study Objective: Gabapentin has been proved to be beneficial in promoting abstinence, decreasing alcohol cravings, and improving mood and sleep quality when given at higher doses; however, data are limited regarding the efficacy and safety of using high‐dose gabapentin as part of the treatment of alcohol withdrawal syndrome ( AWS ). The aim of this study was to evaluate the impact of high‐dose gabapentin on benzodiazepine requirements, alcohol withdrawal symptoms, and hospital length of stay in patients hospitalized with AWS . Design: Retrospective cohort study. Setting: Large academic medical center. Patients: All adults presenting to the emergency department between January 2015 and April 2018 with a diagnosis of severe AWS (Clinical Institute Withdrawal Assessment for Alcohol Scale, Revised [ CIWA ‐Ar] score ≥ 15) and prescribed the institution's alcohol withdrawal agitated delirium protocol were eligible for inclusion in the study. Of these, 50 patients who received high‐dose gabapentin (≥ 1800 mg/day) in the first 48 hours of hospital admission (treatment group) were propensity score–matched to 50 patients who did not receive gabapentin (control group). Measurements and Main Results: Patients who received high‐dose gabapentin required a significantly lower overall amount of benzodiazepines (mean ± SD 109.5 ± 53.4 mg vs 88.5 ± 35.6 mg [lorazepam equivalents], p=0.023) and had a significantly lower mean CIWA ‐Ar score (10.1 ± 4.7 vs 7.7 ± 3.9, p=0.010) and maximum CIWA ‐Ar score (16.0 ± 7.0 vs 12.6 ± 6.1, p=0.016) on day 3 of hospitalization. The high‐dose gabapentin regimen was well tolerated, without an increased risk of oversedation, compared with the control group (Richmond Agitation‐Sedation Scale score < −1: 34% in the treatment group vs 20% in the control group, p=0.115). Patients receiving high‐dose gabapentin had a shorter length of hospital stay (7.4 ± 4.0 days vs 6.0 ± 2.6 days, p=0.034) and increased likelihood of being discharged home (66% vs 88%, p=0.009) compared with the control group. Conclusion: Early initiation of high‐dose gabapentin was associated with a significant reduction in benzodiazepine exposure, faster stabilization of alcohol withdrawal–related symptoms, and shorter hospital length of stay. Future studies evaluating gabapentin's effect on long‐term safety and hospital readmission are warranted.
- 1 May 2007
- Published by Elsevier in Emergency Medicine Clinics of North America
- Vol. 25 (2) , 375-433
Plant Poisoning
- 1 May 2007
- Published by Elsevier in Emergency Medicine Clinics of North America
- Vol. 25 (2) , 375-433
Plant Poisoning
- 1 March 2006
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 26 (1) , 211-226
Brown Recluse Spider Envenomation
- 1 March 2006
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 26 (1) , 211-226
Brown Recluse Spider Envenomation
- 1 March 2006
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 26 (1) , 67-97
Heavy Metal Poisoning: Clinical Presentations and Pathophysiology
- 1 March 2006
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 26 (1) , 67-97
Heavy Metal Poisoning: Clinical Presentations and Pathophysiology